Novo Nordisk(US:NVO) 智通财经网·2025-09-16 15:01Core Viewpoint - Novo Nordisk's new weight loss drug Cagrilintide shows promising results in late-stage clinical trials, leading to a stock price increase of over 2% to $57.12 [1] Group 1: Clinical Trial Results - Cagrilintide demonstrated an average weight loss of 11.8% after 68 weeks in a Phase 3 trial, compared to only 2.3% in the placebo group [1] - The drug is a long-acting insulin analog that increases satiety by mimicking hormones secreted alongside insulin in the pancreas, differing from existing GLP-1 medications [1] Group 2: Company Statements - Martin Holst Lange, Chief Scientific Officer and Executive Vice President of R&D at Novo Nordisk, expressed excitement over the significant weight loss achieved in clinical trials and noted the good tolerability of Cagrilintide [1] - The company anticipates further validation of Cagrilintide's potential in the dedicated Phase 3 RENEW project [1]